Key result
Ibrutinib is linked to reversible new-onset nonischemic cardiomyopathy and ventricular tachycardia.
Why the study?
Does ibrutinib cause cardiomyopathy and ventricular arrhythmia in patients with mantle cell lymphoma?
Population
78-year-old man with relapsed mantle cell lymphoma, history of hypertension, hyperlipidemia, paroxysmal…
Design
Case_report
Follow-up
Approximately 1 year
Authors
Loading...
May support cardiac surveillance during ibrutinib use; hypothesis-generating case report requiring prospective confirmation.
Case Report (n=1)
No
Does ibrutinib cause cardiomyopathy and ventricular arrhythmia in patients with mantle cell lymphoma?
This case provides the first clinical evidence linking ibrutinib to nonischemic cardiomyopathy and ventricular arrhythmias, highlighting the need for cardiac surveillance.
Wallace et al. (2016) conducted a case report in Relapsed mantle cell lymphoma (n=1). Ibrutinib was evaluated. Ibrutinib therapy was associated with the development of new-onset nonischemic cardiomyopathy and ventricular tachycardia, which improved upon discontinuation of the drug.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: